Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 1340617
8. Kimura H, Miura S, Shigematsu T, Ohkubo N, Tsuzuki Y, Kurose I, Higuchi H, Akiba Y, Hokari R, Hirokawa M, Serizawa H, Ishii H: Increased nitric oxide production and inducible nitric oxide synthase activity in colonic mucosa of patients with active ulcerative colitis and Crohn's disease. Dig Dis Sci; 1997 May;42(5):1047-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased nitric oxide production and inducible nitric oxide synthase activity in colonic mucosa of patients with active ulcerative colitis and Crohn's disease.
  • It is postulated that an enhanced production of nitric oxide by inflamed intestine plays a role in the pathophysiology of active inflammatory bowel disease.
  • In this study, systemic NOx concentrations and colonic nitric oxide synthase activity were determined in patients with ulcerative colitis or Crohn's disease.
  • The relationship between these two parameters and disease activity, as well as differences in nitric oxide synthase activity between ulcerative colitis and Crohn's disease, were areas of specific focus.
  • Patients with active ulcerative colitis and Crohn's disease had significantly elevated plasma NOx concentrations; a positive correlation was found between NOx values and inducible nitric oxide synthase activities in the active mucosa of these patients.
  • In active ulcerative colitis, levels of inducible nitric oxide synthase were significantly elevated in both normal and inflamed mucosa, although inducible nitric oxide synthase activity was higher in the latter.
  • These colonic inducible nitric oxide synthase activities correlated well with the results of endoscopic and histologic grading of inflammation.
  • There was no increase in constitutive nitric oxide synthase activity in patients with active ulcerative colitis.
  • However, constitutive nitric oxide synthase activity was significantly increased in the inflamed mucosa in patients with Crohn's disease.
  • In Crohn's disease, elevated inducible nitric oxide synthase activity was found in both normal and inflamed mucosa, with no significant difference between the tissues.
  • Such differences in nitric oxide production in the colonic mucosa possibly reflect the significant differences in the pathophysiology and characteristic clinical features between ulcerative colitis and Crohn's disease.
  • [MeSH-major] Colitis, Ulcerative / metabolism. Colon / metabolism. Crohn Disease / metabolism. Intestinal Mucosa / metabolism. Nitric Oxide / biosynthesis. Nitric Oxide Synthase / biosynthesis

  • Genetic Alliance. consumer health - Crohn Disease.
  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol. 1993 Aug;265(2 Pt 1):G214-8 [7690186.001]
  • [Cites] Dis Colon Rectum. 1990 Dec;33(12):1034-6 [2242698.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Feb;87(4):1620-4 [2154753.001]
  • [Cites] Gut. 1994 Feb;35(2):224-30 [8307474.001]
  • [Cites] Gut. 1988 May;29(5):669-74 [2899536.001]
  • [Cites] Gastroenterology. 1994 Feb;106(2):533-9 [8299918.001]
  • [Cites] J Pharmacol Exp Ther. 1994 Nov;271(2):1114-21 [7525937.001]
  • [Cites] Gut. 1995 May;36(5):718-23 [7541008.001]
  • [Cites] Dig Dis Sci. 1995 Sep;40(9):1859-65 [7555434.001]
  • [Cites] Lancet. 1993 Feb 20;341(8843):465-6 [8094492.001]
  • [Cites] Hepatogastroenterology. 1990 Dec;37 Suppl 2:110-2 [2083921.001]
  • [Cites] Gastroenterology. 1993 Mar;104(3):759-71 [7680014.001]
  • [Cites] Biochem Biophys Res Commun. 1984 Sep 17;123(2):716-23 [6487309.001]
  • [Cites] Gut. 1993 Mar;34(3):375-81 [8472987.001]
  • [Cites] Lancet. 1993 Aug 7;342(8867):338-40 [7687730.001]
  • [Cites] Gastroenterology. 1976 Mar;70(3):439-44 [1248701.001]
  • [Cites] J Clin Invest. 1980 Feb;65(2):357-70 [7356685.001]
  • [Cites] J Exp Med. 1991 Oct 1;174(4):761-7 [1717630.001]
  • [Cites] J Pharmacol Exp Ther. 1993 Jan;264(1):11-6 [7678645.001]
  • [Cites] FASEB J. 1992 Sep;6(12):3051-64 [1381691.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):2002-12 [7504210.001]
  • [Cites] Gastroenterology. 1996 Oct;111(4):871-85 [8831582.001]
  • [Cites] J Leukoc Biol. 1993 May;53(5):498-503 [7684763.001]
  • [Cites] Gastroenterology. 1993 Jul;105(1):60-6 [8390381.001]
  • [Cites] J Exp Med. 1989 May 1;169(5):1543-55 [2497225.001]
  • [Cites] J Clin Invest. 1990 Jan;85(1):264-73 [2404026.001]
  • [Cites] J Lab Clin Med. 1993 Oct;122(4):388-94 [7693839.001]
  • [Cites] Biochem J. 1990 Sep 15;270(3):833-6 [1700698.001]
  • [Cites] Gut. 1992 Dec;33(12):1644-51 [1487166.001]
  • [Cites] Cancer Res. 1993 Jun 1;53(11):2676-82 [8388320.001]
  • [Cites] J Clin Lab Immunol. 1987 Nov;24(3):125-8 [3430561.001]
  • (PMID = 9149061.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 31C4KY9ESH / Nitric Oxide; EC 1.14.13.39 / Nitric Oxide Synthase
  •  go-up   go-down


9. Cannon BC, Feltes TF, Fraley JK, Grifka RG, Riddle EM, Kovalchin JP: Nitric oxide in the evaluation of congenital heart disease with pulmonary hypertension: factors related to nitric oxide response. Pediatr Cardiol; 2005 Sep-Oct;26(5):565-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nitric oxide in the evaluation of congenital heart disease with pulmonary hypertension: factors related to nitric oxide response.
  • Inhaled nitric oxide (NO) has been used in the preoperative evaluation of patients with congenital heart disease and pulmonary hypertension.
  • The purpose of this study was to characterize responses in pulmonary vascular resistance (PVR) to oxygen and increasing doses of NO during cardiac catheterization and to determine if any related factors affect the response of the pulmonary vascular bed to NO.
  • A prospective analysis of 42 patients (median age, 3.0 years) with congenital heart disease and pulmonary hypertension who underwent NO testing was performed.
  • Changes in pulmonary artery pressure, PVR, and SVR were assessed.
  • [MeSH-major] Bronchodilator Agents / pharmacology. Heart Defects, Congenital / drug therapy. Hypertension, Pulmonary / drug therapy. Nitric Oxide / pharmacology. Oxygen / pharmacology. Vascular Resistance / drug effects
  • [MeSH-minor] Administration, Inhalation. Adolescent. Adult. Blood Pressure / drug effects. Cardiac Catheterization. Child. Child, Preschool. Dose-Response Relationship, Drug. Down Syndrome / epidemiology. Drug Therapy, Combination. Female. Humans. Infant. Male. Oxygen Consumption / drug effects. Prospective Studies. Pulmonary Artery. Risk Factors. Treatment Outcome






Advertisement